Pines A, Sturdee DW, MacLennan AH (2012) Quality of life and the role of the menopausal hormone therapy. Climacteric 15:213–216PubMedCrossRef

Nelson HD (2004) Commonly used types of postmenopausal estrogen for treatment of hot flushes: scientific review. JAMA 291:1610–1620PubMedCrossRef

Vernet Mdel M, Checa MA, Macia F, Casamitjana M, Carreras R (2006) Influence of hormone replacement therapy on the accuracy of screening mammography. Breast J 12:154–158PubMedCrossRef

Barnabei VM, Cochrane BB, Aragaki AK, Women’s Health Initiative Investigators et al (2005) Menopausal symptoms and treatment related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol 105:1063–1073PubMedCrossRef

National Institutes of Health; State-of-the-Science Panel (2005) National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 142:1003–1013CrossRef

Schiff I, Tulchinsky D, Cramer D, Ryan KJ (1980) Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 244:1443–1445PubMedCrossRef

Suckling J, Kennedy R, Lethaby A, Roberts H (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Sys Rev (4):CD001500

Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA (2009) Oestrogen therapy for urinary incontinence in postmenopausal women. Cochrane Database Syst Rev (4):CD001405

Townsend MK, Curhan GC, Resnick NM, Grodstein F (2010) The incidence of urinary incontinence across Asian, black, and white women in the United States. Am J Obstet Gynecol 202:378.e1–378.e7CrossRef

Hendrix SL, Cochrane BB, Nygaard IE et al (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935–948PubMedCrossRef

Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T, HERS Research Group (2001) Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Study. Obstet Gynecol 97:116–120PubMedCrossRef

Raz R, Stamm WE (1993) A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329:753–756PubMedCrossRef

Eriksen BC (1999) A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 80:1072–1079CrossRef

Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR (1998) Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 83:2239–2243PubMed

Cauley JA, Robbins J, Chen Z, Women’s Health Investigators et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative Randomized Trial. JAMA 290:1729–1738PubMedCrossRef

Jackson RD, LaCroix AZ, Gass M, Women’s Health Investigators et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683PubMedCrossRef